EUVIMEDEUVIMED entdecken
Crossref

Abstract 6509: BPR-32360402, a Single-Molecule Liver-Directed Dual PCSK9/LPA RNAi Therapeutic, Achieves Durable and Comprehensive Atherogenic Lipoprotein Reduction in Non-Human Primates

Yu Chen, YANG LING, XIWEN CHENG, Teng Ai, jiachuan duan, haoxi huang

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.6509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Yu Chen und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elevated low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] are independent contributors to residual atherosclerotic cardiovascular disease (ASCVD) risk. RNA interference (RNAi) therapeutics targeting either PCSK9 or LPA have demonstrated robust and durable reductions in LDL-C and Lp(a), respectively. However, a single-molecule strategy capable of simultaneously suppressing both pathways may enable more comprehensive reduction of atherogenic lipoprotein burden. Research Questions/Hypothesis: We evaluated whether BPR-32360402, a novel liver-directed, dual-targeting RNAi therapeutic, could achieve potent and durable simultaneous suppression of PCSK9 and LPA while maintaining favorable pharmacokinetic and safety profiles.

Methods

Efficacy was evaluated in dual-humanized mice (assessing circulating human PCSK9 and apo(a) proteins) and cynomolgus monkeys (assessing circulating PCSK9, Lp(a), LDL-C, total cholesterol, and ApoB) following a single subcutaneous administration and benchmarked against inclisiran and olpasiran. Liver pharmacokinetics were evaluated by area under the concentration-time curve (AUC) analysis. Safety and tolerability were characterized in dose-range finding toxicology studies in rats and nonhuman primates (NHPs).

Results

In dual-humanized mice, BPR-32360402 induced dose-dependent suppression of circulating PCSK9 and Apo(a). PCSK9 reduction was comparable to inclisiran at equivalent molar doses, while apo(a) suppression exceeded that achieved with olpasiran. In cynomolgus monkeys, a single administration of BPR-32360402 produced durable lipid lowering for more than 12 weeks. Compared with inclisiran, BPR-32360402 achieved greater maximal reductions in LDL-C (71.8% vs. 60.7%) and ApoB (76.5% vs. 59.3%), while simultaneously reducing Lp(a) by up to 96.3%(Fig1). Liver exposure of BPR-32360402 was comparable to single-target RNAi therapeutics, supporting preserved liver-selective delivery. No hepatotoxicity or systemic toxicity was observed; the no-observed-adverse-effect level (NOAEL) was 200 mg/kg in rats and 300 mg/kg in NHPs.

Conclusion

Dual targeting of PCSK9 and LPA through the single-molecule RNAi therapeutic BPR-32360402 enabled durable and comprehensive reduction of atherogenic lipoproteins in preclinical models, including NHPs, while maintaining favorable tolerability and liver-selective exposure. These findings support further clinical development of BPR-32360402 for residual ASCVD risk management.

Zitieren

APA

Chen, Y., LING, Y., CHENG, X., Ai, T., duan, J., & huang, H. (2026). Abstract 6509: BPR-32360402, a Single-Molecule Liver-Directed Dual PCSK9/LPA RNAi Therapeutic, Achieves Durable and Comprehensive Atherogenic Lipoprotein Reduction in Non-Human Primates. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.6509

Vancouver

Chen Y, LING Y, CHENG X, Ai T, duan J, huang H. Abstract 6509: BPR-32360402, a Single-Molecule Liver-Directed Dual PCSK9/LPA RNAi Therapeutic, Achieves Durable and Comprehensive Atherogenic Lipoprotein Reduction in Non-Human Primates. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.6509

BibTeX
@article{Chen2026,
  author = {Chen, Yu and LING, YANG and CHENG, XIWEN and Ai, Teng and duan, jiachuan and huang, haoxi},
  title = {Abstract 6509: BPR-32360402, a Single-Molecule Liver-Directed Dual PCSK9/LPA RNAi Therapeutic, Achieves Durable and Comprehensive Atherogenic Lipoprotein Reduction in Non-Human Primates},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.6509}
}
Kostenlos starten →